World Sleep Industry ENCYCLOPEDIA

Suvorexant

2.1.1

Drug identity, orexin mechanism, and category boundaries

Suvorexant is a prescription sedative-hypnotic and a dual orexin receptor antagonist. Orexin A and orexin B are neuropeptides that help maintain the drive to stay awake. By blocking both OX1R and OX2R, suvorexant reduces wake signaling and can facilitate sleep. It is not melatonin, an antihistamine, a benzodiazepine, or a Z-drug. A different target does not make the resulting sleep “natural” or eliminate sedation-related harm. Reducing wake drive does not correct every cause of insomnia or guarantee restoration of any particular sleep architecture.

The mechanism is relevant to the abnormal orexin system in narcolepsy, which is why narcolepsy is a contraindication in some current labeling. Sleep paralysis, vivid perceptions while falling asleep or awakening, and brief leg weakness resembling cataplexy after a dose do not by themselves establish narcolepsy, but their timing, duration, and associated awareness should be documented and promptly reviewed. Suvorexant shares a broad class with other dual orexin receptor antagonists, yet the agents differ in half-life, interactions, strengths, and country-specific authorization. They are not interchangeable by milligrams, tablet count, or brand family.

Sleep-onset and maintenance roles, evidence limits, and causal assessment

Current US labeling authorizes suvorexant for adult insomnia characterized by difficulty with sleep onset and/or sleep maintenance. Randomized trials found that certain doses reduced sleep latency and wake after sleep onset and increased total sleep time on a group-average basis. Higher studied doses did not produce proportionately greater efficacy but generated more adverse reactions. A professional guideline offers only a weak suggestion for adult sleep-maintenance insomnia, based on low-quality evidence. A statistically significant mean difference does not show that every person will have a meaningful nighttime or daytime benefit.

“Fewer awakenings” must be interpreted alongside adequate sleep opportunity, next-day alertness, and actual function, rather than a single-night wearable score. Baseline assessment should verify schedule, time in bed, caffeine and alcohol exposure and screen for sleep apnea, narcolepsy, restless legs, pain, nocturia, circadian misalignment, depression, mania, anxiety, substance use, and risk of self-harm. Cognitive behavioral therapy for insomnia remains part of foundational care for chronic insomnia. Persistence for seven to ten days, worsening, or a new cognitive or behavioral change calls for reassessment of medical, psychiatric, circadian, or medication causes.

Exact timing, a full sleep window, and pharmacokinetic implications

Suvorexant should be used at the lowest effective dose under the current local label for the exact product and taken only when preparing for bed. Current US labeling specifies no more than once nightly, within about 30 minutes of going to bed, with at least seven hours before the planned awakening. A person should not add a dose when one has already been taken, dosing is uncertain, too little sleep time remains, or caregiving, alarms, driving, or equipment use may still be necessary. A missed dose is not doubled the next day, and failure to feel sleepy immediately is not a reason to add a tablet or combine another hypnotic.

The median peak concentration under fasting conditions is about two hours, with a wide individual range. A high-fat meal can delay the peak by roughly another hour and a half without materially changing overall exposure, so slower onset after food is not evidence that more medicine is needed. The mean elimination half-life is about twelve hours; nightly use reaches steady state in roughly three days and produces some accumulation. These group pharmacokinetic values cannot predict when an individual is completely alert. Exposure may be higher in women and in people with obesity, particularly women with obesity, and hepatic function or interacting medicines can further change residual risk.

Next-day function, complex sleep behavior, and sleep-transition phenomena

Suvorexant can reduce next-day wakefulness, reaction speed, judgment, balance, and driving ability even when taken as prescribed. Impairment may occur without obvious subjective sleepiness and cannot be reliably excluded by an ordinary interview or by feeling awake. Too little time for sleep, a higher dose, alcohol or another central nervous system depressant, and medicines that raise suvorexant concentrations increase the risk. In some people, depressant effects can persist for several days after discontinuation. Anyone with somnolence, dizziness, slow reactions, visual disturbance, or unsteady gait should not drive, cycle, climb, or perform hazardous work; older adults require particular attention to nighttime falls.

Complex sleep behaviors include walking, driving, preparing or eating food, making calls, having sex, or performing other activities while not fully awake, often without later memory. They can occur after a first or later exposure and with or without alcohol or another depressant. A suspected episode calls for immediate discontinuation of further self-dosing, protection of the person and others, and contact with the prescriber. Sleep paralysis, hallucinations at sleep onset or awakening, and brief cataplexy-like weakness form a different group of sleep-wake transition events. They also require review but should not be collapsed into complex sleep behavior, an ordinary nightmare, syncope, or seizure.

Adverse effects, interactions, and special populations

Somnolence is the most common adverse reaction; headache, dizziness, abnormal dreams, dry mouth, and gastrointestinal symptoms may also occur. Worsening depression, suicidal thoughts, a new abnormal behavior, or a marked mental-status change requires immediate assessment and limitation of access to excess tablets. Alcohol, opioids, benzodiazepines, tricyclic antidepressants, sedating antihistamines, antipsychotics, anesthetics, and other hypnotics can add to central nervous system or respiratory depression. A patient should not try to “cancel” an interaction by independently raising or lowering either medicine.

Suvorexant is metabolized mainly through CYP3A. Strong inhibitors can substantially raise exposure, whereas strong inducers can reduce effectiveness; moderate inhibitors, grapefruit products, and digoxin also warrant specific reconciliation. Some current labeling does not recommend use in severe hepatic impairment, while renal and mild-to-moderate hepatic decisions still depend on the exact product. Evidence is insufficient in severe obstructive sleep apnea or severe chronic obstructive pulmonary disease, and small studies in milder disease do not establish absence of respiratory risk. Pediatric safety and effectiveness are unestablished. Human pregnancy data are insufficient; the drug and a metabolite enter breast milk in low concentrations, but effects on a breastfed infant are unknown, requiring individualized decisions.

Abuse, dependence, inappropriate discontinuation, and overdose

Suvorexant is a Schedule IV controlled substance in the United States and has abuse potential. Closer monitoring is appropriate with prior alcohol or drug misuse, use beyond the prescription, daytime dosing, pursuit of a sedative effect, early refills, or multiple sources. Abuse, physical dependence, and addiction are not synonyms. Addiction involves loss of control and continued use despite harm; physical dependence produces physiologic withdrawal after stopping; tolerance is diminished effect at the same exposure. Completed clinical trials did not identify clear physical dependence or withdrawal after discontinuation, but this does not prove that long exposure, excessive doses, multiple drugs, or high-risk populations can never have stopping difficulties.

After ongoing use, a person should not independently escalate, split a dosage form that cannot be divided accurately, repeatedly experiment across a night, or substitute alcohol or another hypnotic. Whether to stop directly, change frequency, or transition gradually should be decided with the prescriber using the actual product, dose, duration, co-sedatives, recurrent insomnia, and mental state; a taper schedule from another drug should not be imported automatically. Overdose most clearly produces prolonged or increasing somnolence and may include abnormalities of consciousness, breathing, circulation, or coordination. Accidental, repeated, or intentional excess requires immediate emergency or poison-center advice, without waiting for the person to awaken, inducing vomiting, or attempting a home antidote.

Reassessment, storage, and encyclopedia boundaries

Reassessment should record the real dosing time, food, sleep opportunity, sleep latency, wake after sleep onset, total sleep time, morning alertness, driving or fall near misses, abnormal dreams, sleep paralysis, brief weakness, complex sleep behavior, and observations from a bed partner or household member. If benefit is only subjective sedation while daytime function worsens, the symptom pattern does not fit the medicine, a full sleep window cannot be protected, serious behavioral or psychiatric changes occur, or risk exceeds benefit, the plan should change rather than roll into automatic refills. Behavioral treatment, schedule management, and treatment of underlying disease continue in parallel.

The medicine should remain in its original container or an identifiable compliant dispenser, stored at the labeled temperature away from moisture and light and secured from children, visitors, and anyone without a prescription. A controlled medicine should never be shared, sold, or stockpiled where it is easily reached during an emotional crisis. Authorized indications, tablet strengths, maximum dose, control status, and special-population rules differ by country and product, so the current local label must be checked. This entry explains mechanism, evidence, and risk boundaries; it does not provide a personal dose, market orexin antagonism as free of dependence, falls, or next-day impairment, or promise treatment of narcolepsy, sleep apnea, dementia, or every cause of insomnia.